CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
ABT-888 +1 moredrug
Likely dose
mFOLFOX-6 85 mg/M2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01489865
NCT01489865Phase 2Completed
CompareCT.gov

A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer

Georgetown University·interventional·Posted Dec 12, 2011·Updated Nov 6, 2025

In Brief

A Phase 2 clinical trial evaluating ABT-888 and mFOLFOX-6 for Metastatic Pancreatic Cancer. Completed, enrolled 64 participants across 1 site.

Detailed Summary

People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with metastatic pancreatic cancer. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
CollaboratorsAbbott

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 12, 2011
Enrollment StartJan 3, 2011
Primary CompletionDec 26, 2018
Study CompletionDec 7, 2023
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 14.6 years ago

Interventions

ABT-888drug

ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle

mFOLFOX-6drug

Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3